TGFB1 and neoplasm: Targeting the molecular pathways driving EMT may enhance chemosensitivity; for instance, inhibiting TGF-β signaling can prevent EMT and reverse the associated resistance, thereby making tumor cells more susceptible to chemotherapy [123].